Experimental combo aims to tackle returning brain tumors
NCT ID NCT07629089
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether combining vorasidenib (a targeted therapy) with lomustine (a chemotherapy) is safe for people with recurrent IDH-mutant gliomas, a type of brain cancer. About 24 adults whose tumors have returned will receive different doses to find the best one. The goal is to prepare for a larger study on whether this combo can help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vorasidenib and lomustine
- What this could lead to
- If successful, this could point toward a new combination treatment for recurrent IDH-mutant brain tumors.
- What could go wrong
- This is a very early phase 1 trial with only 24 participants, so safety and dosing are still being figured out. The combination may not work or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UMPC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple dye help surgeons see brain tumors in real time?
- Mapping the hidden toll of brain radiation on young minds
- Could an ALS drug clear the fog of chemo brain?
- Electric field device tested for Hard-to-Treat brain tumor
- Surgical flap opens door to brain tumors in small safety trial
- New group program aims to boost Well-Being in brain cancer patients